BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline Including OMNI-EGFR Inhibitor for NSCLC December 15, 2025
Immutep and Dr. Reddy’s enter Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 15, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch Ph 2a dose-expansion trial with TTX-MC138 December 15, 2025
Crescent Biopharma Announces Partnership with Kelun-Biotech and $185M Private Placement for Next Gen Therapeutics for Solid Tumors December 9, 2025
First US Commercial Sale of KOMZIFTI™ Triggers $135M Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for TNBC December 9, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness December 9, 2025
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours December 2, 2025
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Biotherapeutics in Oncology December 2, 2025
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics December 2, 2025
Vaximm signs non-binding term sheet with BCM Europe (BCME) for a potential exclusive worldwide licence for VXM01 December 2, 2025
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth December 2, 2025
KaliVir Immunotherapeutics and Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors November 24, 2025
Gazyva® IV Infusion 1000 mg revised to allow combination therapy with the Venclexta® Tablets 10 mg, 50 mg, and 100 mg for 1L CD20-positive CLL/SLL November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
